Search
Sumario de resultados
TIpos de contenido
Fecha
-
NewAlmirall launches new call to establish partnerships in innovative therapies for skin dise...
AlmirallShare, the company’s R&D open innovation platform, and looks for partnering opportunities for new assets in order to offer breakthrough innovation and accelerate the generation of new
-
NewThe EMA validates Algenex's CrisBio® technology platform, for the manufacture of vaccines...
This European recommendation has validated the use of this technology to produce recombinant biologics and biocomponents
-
NewBCN HEALTH has participated in the "Global Thalassaemia Review 2021 Report" developed by t...
With the data obtained in the targeted literature, a cost-of-illness model has been developed to determine the cost of thalassaemia
-
New#InterviewBiospain2021 | The company born drinking a beer that ended up as the first to de...
3P Biopharmaceuticals operates globally, with 19 active projects worldwide and has positioned itself, after a difficult start in 2006, as a leader in the biologics manufacturing field in Spain
-
NewA FECYT report concludes that the entire innovation incentive scheme needs to be redesig...
GENESIS Biomed has participated in the preparation of the THINK TANK report "Patenting and/or publishing" by the FECYT, which covers the debate on publishing research or its transfer and exploitation
-
NewPersonalised medicine increases its activity by 40% in the last year and is becoming more ...
Precision medicine and personalised medicine products or services have gone from representing 12% of total launches to 52% in 2020. Navarra, which is hosting Biospain 2021, is one of the pioneering
-
NewORYZON receives approval to start EVOLUTION Phase IIb trial with vafidemstat in schizophre...
Clinical Trial Application approved by Spanish Drug Agency Primary objectives: to assess the effect of vafidemstat to address negative and cognitive symptoms in schizophrenia Second Phase IIb study of
-
NewORYZON presents safety and efficacy data of vafidemstat from the Phase II ESCAPE trial in...
Vafidemstat was safe and well tolerated Confirmed anti-inflammatory activity of vafidemstat Vafidemstat reduced exacerbated CD4+ T cell activation and inflammatory cytokine release Fast recovery of
-
NewCorify Care raises €2.35M to translate its cardiac mapping technology to the market
The investment round is led by Clave Capital, counting with investment from CDTI through its Innvierte program and the support from Genesis Biomed
-
NewYsios Capital’s portfolio company CVRx Inc. prices IPO on NASDAQ
This is a major achievement for Ysios as CVRx is its fifth portfolio company to be listed on NASDAQ, and the second within just three months.
-
EventBIO Asia-Taiwan 2021
Jointly organized by the Biotechnology Innovation Organization (BIO) and the Taiwan Bio Industry Organization (Taiwan BIO), BIO Asia–Taiwan has grown over the years to it
-
NewPreparation is key: brief checklist how to bring IVD MD into compliance with EU IVDR
El IVDR evolucionó a partir de la IVDD para establecer un “marco más sólido, transparente, predecible y sostenible para los IVDs”
-
CompanyWorld Courier
-
New2020 AseBio Report shows huge jump in Spanish biotechnology in pandemic year
Biotech companies launched 70% more products and services to market and Spain moved to eighth in the world in scientific production in biotechnology
-
NewMoirai Biodesign creates an innovative synthetic RNA design software
Moirai Biodesign – a biotech startup located at the Barcelona Scientific Park, pioneer in the development of RNA-based solutions for the development of new therapies and diagnostic systems– has
-
NewORYZON to present new clinical data and corporate updates at international conferences in...
Emerging Biotech Company Showcase organizado por NewYorkBIO y la Bolsa de Nueva York Spring European Virtual MidCap Event 31º Congreso Europeo de Microbiología Clínica y Enfermedades Infecciosas
-
New#NewMember | "AseBio allows to know the latest market trends and connect with the Spanish ...
Meet our new memeber DSM Pentapharm. We talk with Kally Wong, con la Business Director, Pharma and Head of R&D of the company.
-
NewMore than 160 spanish biotech companies seek out solutions for a greener industry
Most of these companies will be at the most important annual event for the sector, BIOSPAIN 2021, which will be held in Pamplona-Iruña from 27th September to 1rst October
-
NewORYZON announces FDA approval of IND for PORTICO, a Phase IIb trial with vafidemstat in Bo...
Recruitment ongoing in Europe. Primary objectives: to assess the effect of vafidemstat to address agitation and aggression and to improve overall disease
-
EventNutrEvent 2022
-
EventAgeingFIT 2022